Chang J, Wu YL, Lu S, Wang J, et al. Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. Lung Cancer 2021;165:71-81.
PMID: 35093625